Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:52 UTC |
---|
Update Date | 2022-03-07 02:52:04 UTC |
---|
HMDB ID | HMDB0015648 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Fesoterodine |
---|
Description | Fesoterodine, also known as toviaz, belongs to the class of organic compounds known as diphenylmethanes. Diphenylmethanes are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups. Fesoterodine is a drug which is used for the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence). Therefore, acting as a competitive muscarinic receptor antagonist, fesoterodine ultimately acts to decrease the detrusor pressure by its muscarinic antagonism, thereby decreasing bladder contraction and consequently, the urge to urinate. Fesoterodine is a very strong basic compound (based on its pKa). This results in the inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder. The 5-hydroxymethyl metabolite, which exhibits an antimuscarinic activity. In-vivo the fesoteridine prodrug is broken down into its active metabolite, 5-hydroxymethyl tolterodine (5-HMT), by plasma esterases. It is an antimuscarinic prodrug used for treating overactive bladder syndrome. Mouse, Intravenous, NOAEL: 10 mg/kg. Fesoterodine is only found in individuals that have used or taken this drug. Mouse, Oral, LD50: ~ 316 mg/kg. Extensive metabolism via CYP2D6 and CYP3A4 into inactive metabolites. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. |
---|
Structure | CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1 |
---|
Synonyms | Value | Source |
---|
Fesoterodine fumarate | HMDB | Toviaz | HMDB |
|
---|
Chemical Formula | C26H37NO3 |
---|
Average Molecular Weight | 411.5769 |
---|
Monoisotopic Molecular Weight | 411.277344055 |
---|
IUPAC Name | 2-[(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate |
---|
Traditional Name | fesoterodine |
---|
CAS Registry Number | 286930-03-8 |
---|
SMILES | CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C |
---|
InChI Identifier | InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1 |
---|
InChI Key | DCCSDBARQIPTGU-HSZRJFAPSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as diphenylmethanes. Diphenylmethanes are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Diphenylmethanes |
---|
Direct Parent | Diphenylmethanes |
---|
Alternative Parents | |
---|
Substituents | - Diphenylmethane
- Phenol ester
- Phenoxy compound
- Benzyl alcohol
- Aralkylamine
- Amino acid or derivatives
- Carboxylic acid ester
- Tertiary amine
- Tertiary aliphatic amine
- Carboxylic acid derivative
- Monocarboxylic acid or derivatives
- Hydrocarbon derivative
- Organooxygen compound
- Organonitrogen compound
- Amine
- Organic oxide
- Organopnictogen compound
- Alcohol
- Carbonyl group
- Organic oxygen compound
- Organic nitrogen compound
- Primary alcohol
- Aromatic alcohol
- Aromatic homomonocyclic compound
|
---|
Molecular Framework | Aromatic homomonocyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Not Available | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatized |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Fesoterodine GC-MS (Non-derivatized) - 70eV, Positive | splash10-03k9-8779000000-2e606385c85d52b6ad73 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fesoterodine GC-MS (1 TMS) - 70eV, Positive | splash10-00dj-9457500000-02377439d5649ab75cde | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fesoterodine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fesoterodine 10V, Positive-QTOF | splash10-03kc-3009400000-978607a6967c2d825788 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fesoterodine 20V, Positive-QTOF | splash10-00dl-7119000000-6475282629458a0a7258 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fesoterodine 40V, Positive-QTOF | splash10-00dl-9112000000-b09c728a097046fe179f | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fesoterodine 10V, Negative-QTOF | splash10-03di-1105900000-caf232db2b163610a883 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fesoterodine 20V, Negative-QTOF | splash10-03yu-4319400000-e5681e839bc048241795 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fesoterodine 40V, Negative-QTOF | splash10-0uy0-9633000000-84e9d271fc2bbafaea1c | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fesoterodine 10V, Positive-QTOF | splash10-03di-0397500000-ea0138d5a13e76b11261 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fesoterodine 20V, Positive-QTOF | splash10-03di-2798100000-2a503c5f3e4b7e1a650f | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fesoterodine 40V, Positive-QTOF | splash10-00kf-5691000000-e26eea698dfefe6f3b7e | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fesoterodine 10V, Negative-QTOF | splash10-03di-3001900000-7d7d96bfcf644443845b | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fesoterodine 20V, Negative-QTOF | splash10-022i-8769600000-438b20dbac6e0f5ac5c6 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fesoterodine 40V, Negative-QTOF | splash10-00di-7497000000-4a55b2cc2b5ff6962d0f | 2021-10-11 | Wishart Lab | View Spectrum |
|
---|
General References | - Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X, Duczynski G, Gandelman K: Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9. doi: 10.1111/j.1365-2125.2011.04007.x. [PubMed:21545485 ]
- Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC: The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem. 2009;16(33):4481-9. [PubMed:19835561 ]
|
---|